LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

JNJ

154.71

+0.26%↑

MRK

131.21

+0.28%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

JNJ

154.71

+0.26%↑

MRK

131.21

+0.28%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

JNJ

154.71

+0.26%↑

MRK

131.21

+0.28%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

JNJ

154.71

+0.26%↑

MRK

131.21

+0.28%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

JNJ

154.71

+0.26%↑

MRK

131.21

+0.28%↑

ABBV

166.41

+1.24%↑

Home・Stock List・Novo Nordisk A-S

Novo Nordisk A-S

Closed

Sector Healthcare

131.87 -0.86

Buy Sell

Overview

Share price change

24h

Current

Min

131.37

Max

131.92

Key metrics
By Trading Economics
Income	3.1B 22B
Sales	7.1B 66B
P/E Sector Avg	43.245 23.904
EPS	4.91
Dividend yield	1.128
Profit margin	38.273
EBITDA	3.4B 29B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+12.21 upside

Dividends
By Dow Jones
Dividend yield Sector Avg	1.13% 7.76%

Market Stats
By TradingEconomics
Market Cap	15B 450B
Previous open	132.73
Previous close	131.87

News Sentiment

By Acuity

50%

124 / 368 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

128.43 / 132.92 Support & Resistance

Novo Nordisk A-S Chart

Related News

3 May 2024, 13:51 UTC

Acquisitions, Mergers, Takeovers

FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal

2 May 2024, 06:58 UTC

Earnings

Novo Nordisk Lifts Guidance as Blockbuster Drug Demand Shows No Signs of Abating -- Update

2 May 2024, 06:08 UTC

Peer Comparison

Price change

Novo Nordisk A-S Forecast

Price Target

By TipRanks

12.21% upside

12 Months Forecast

Average 148 USD 12.21%

High 163 USD

Low 130 USD

Based on 7 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Novo Nordisk A-S - Dist in the past 3 months.

Technical Score

By Trading Central

128.43 / 132.92Support & Resistance

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

124 / 368 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.